Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPA100 in Essential Hypertension
NCT01237223Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aliskiren, amlodipine in essential hypertension, sponsored by Novartis. Started Oct 2010; status: completed.
02
Drugs
aliskirenamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01237223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01237223.